GlassScriptPhysician profile
Joanne Guerra
NPI 1134672215
$5,298.27
in general payments reported to CMS, 2019-2025
22 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $848 · 2023: $1,235 · 2024: $1,184 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.64 | 2021-2025 | |
| Melinta Therapeutics, LLC | $784.96 | 2021-2025 | Rezzayo, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $502.43 | 2022-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $434.36 | 2021-2025 | Zerbaxa, Recarbrio, Dificid |
| La Jolla Pharmaceutical Company | $407.16 | 2021-2025 | Xerava, Zevtera |
| Shionogi INC | $365.34 | 2021-2024 | Fetroja |
| Gilead Sciences, INC. | $353.64 | 2021-2025 | Epclusa |
| Ferring Pharmaceuticals INC. | $281.04 | 2022-2025 | Rebyota |
| Janssen Pharmaceuticals, INC | $254.07 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $144.45 | 2021-2023 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $115.03 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $96.19 | 2022 | |
| Chiesi USA, INC. | $91.85 | 2021-2022 | |
| Invivyd INC | $50.37 | 2025 | Pemgarda |
| Baxter Healthcare | $46.11 | 2023 | Hillrom - Life 2000 Ventilation System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $34.08 | 2021 | |
| Electromed, INC. | $30.14 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $20.30 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.59 | 2021 | |
| Cormedix INC. | $17.89 | 2025 | Defencath |
| Insmed, INC. | $17.31 | 2025 | Arikayce |
| Philips North America LLC | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Guerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.